Protective Effect of Glucagonlike Peptide-1 on Reperfusion Injury in Patients With Acute Myocardial Infarction
Phase of Trial: Phase IV
Latest Information Update: 05 Feb 2018
Price : $35 *
At a glance
- Drugs Liraglutide (Primary)
- Indications Postmyocardial infarction; Reperfusion injury
- Focus Therapeutic Use
- 31 Aug 2018 Biomarkers information updated
- 04 Feb 2016 Planned number of patients changed from 72 to 90 as per ClinicalTrials.gov record.
- 04 Feb 2016 Planned End Date changed from 1 Dec 2015 to 1 Mar 2016 as per ClinicalTrials.gov record.